Assembly Biosciences (ASMB) Stock Price, News & Analysis

Company Overview

Assembly Biosciences is a clinical-stage biotechnology company focused on developing oral antiviral therapies for viral infections. Its research programs target hepatitis B virus (HBV) and herpesviruses, including herpes simplex virus.

The company’s pipeline includes investigational antiviral candidates designed to interfere with key steps in viral replication. Assembly has also worked with Gilead Sciences on antiviral development, including programs targeting herpesviruses. Its therapies remain under investigation and are not approved medicines.

Based in South San Francisco, California, Assembly Biosciences conducts drug research and development with the goal of addressing significant unmet needs in viral disease treatment.

Key Stats

• Today's Range: $19.22 to $20.48
• 50-Day Range: $19.51 to $36.60
• 52-Week Range: $19.20 to $39.71
• Volume: 119,767 shs
• Average Volume: 195,248 shs
• Market Capitalization: $412.09 million
• P/E Ratio: 19.79
• Dividend Yield: N/A
• Price Target: $46.50
• Consensus Rating: Moderate Buy

Assembly Biosciences Stock Analysis - MarketRank™

Assembly Biosciences scored higher than 49% of companies evaluated by MarketBeat, and ranked 435th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Assembly Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Assembly Biosciences has a consensus price target of $46.50, representing about 130.4% upside from its current price of $20.18.

Amount of Analyst Coverage

Assembly Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: -97.81%

Earnings Growth

Earnings for Assembly Biosciences are expected to decrease by -97.81% in the coming year, from $2.28 to $0.05 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Assembly Biosciences is 21.93, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.74.

Price to Earnings Ratio vs. Sector

The P/E ratio of Assembly Biosciences is 21.93, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 35.36.

Price to Book Value per Share Ratio

Assembly Biosciences has a P/B Ratio of 1.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.44% of the float of Assembly Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Assembly Biosciences has a short interest ratio ("days to cover") of 17, which indicates bearish sentiment.

Change versus previous month

Short interest in Assembly Biosciences has recently increased by 4.09%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Assembly Biosciences does not currently pay a dividend.

Dividend Growth

Assembly Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: -0.68

News Sentiment

Assembly Biosciences has a news sentiment score of -0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Assembly Biosciences this week, compared to 3 articles on an average week.

MarketBeat Follows

3 people have added Assembly Biosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Assembly Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $237,696.00 in company stock.

Percentage Held by Insiders

3.50% of the stock of Assembly Biosciences is held by insiders.

Percentage Held by Institutions

19.92% of the stock of Assembly Biosciences is held by institutions.

Company Calendar

• Last Earnings: 11/12/2026
• Today: 11/13/2026
• Jefferies Global Healthcare Conference: 11/17/2026
• UBS Global Biopharma Conference 2026: 11/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ASMB
• CIK: 1426800
• Web: www.assemblybio.com
• Phone: (833) 509-4583
• Fax: 646-706-5101
• Employees: 73
• Year Founded: 2005

Price Target and Rating

• Average Price Target for Assembly Biosciences: $46.50
• High Price Target: $50.00
• Low Price Target: $43.00
• Potential Upside/Downside: +129.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.02
• Trailing P/E Ratio: 19.97
• Forward P/E Ratio: 404.96
• P/E Growth: N/A
• Net Income: -$6.12 million
• Net Margins: -0.06%
• Pretax Margin: -0.06%
• Return on Equity: -0.02%
• Return on Assets: -0.02%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.99
• Quick Ratio: 13.99

Sales & Book Value

• Annual Sales: $72.30 million
• Price / Sales: 5.70
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $13.04 per share
• Price / Book: 1.55

Miscellaneous

• Outstanding Shares: 20,360,000
• Free Float: 19,648,000
• Market Cap: $412.25 million
• Optionable: Optionable
• Beta: 1.26